[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100522031":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":18,"centralContacts":23,"locations":29,"responsibleParty":41,"collaborators":10,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":46,"sex":52,"minAge":53,"maxAge":10,"enrollmentInfo":54,"targetDuration":10,"studyType":57,"phases":10,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":66,"whyStopped":10,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Beijing Tiantan Hospital","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"Registry Study on Microcirculatory Disorders in Acute Ischemic Stroke",null,"Establish a Chinese registry platform for microcirculatory disorders after acute ischemic stroke; use this registry platform to record the prevalence, diagnosis and treatment information, and prognosis of microcirculatory disorders after acute ischemic stroke.",{"label":13,"type":10,"description":14,"interventionNames":10},"Registry Study on Microcirculatory Disorders in Ischemic Stroke during Recovery Period","Establish a national registry platform for microcirculatory disorders in ischemic stroke during recovery period; use this registry platform to record the prevalence, diagnosis and treatment information, and prognosis of microcirculatory disorders in ischemic stroke during recovery period.",{"label":16,"type":10,"description":17,"interventionNames":10},"Registry Study on Microcirculatory Disorders in CSVD","Establish a national registry platform for microcirculatory disorders in CSVD; use this registry platform to record the prevalence, diagnosis and treatment information, and disease outcome of microcirculatory disorders in CSVD.",[19],{"name":20,"affiliation":21,"role":22},"Yilong Wang, PhD+MD","Beijing Tiantan Hospital, Capital Medical University, Beijing, China","PRINCIPAL_INVESTIGATOR",[24],{"name":20,"role":25,"phone":26,"phoneExt":27,"email":28},"CONTACT","0086-010-67092222","0","yilong528@aliyun.com",[30],{"facility":5,"status":10,"city":31,"state":10,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":10},"Beijing","100050","China","CN",{"type":36,"coordinates":37},"Point",[38,39],116.39723,39.9075,{"lat":39,"lon":38},{"type":22,"investigatorFullName":42,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"yilong Wang","Vice President of Beijing Tiantan Hospital","100522031","a-registry-study-of-microcirculation-disorder-after-cerebral-small-vessel-disease-and-ischemic-stroke-100522031",false,"NCT06077305","A Registry Study of Microcirculation Disorder After Cerebral Small Vessel Disease and Ischemic Stroke","A Registry Study of Microcirculation Disorder After Cerebral Small Vessel Disease and Ischemic Stroke, MODEST, Research Protocol","MODEST","Inclusion Criteria:\n\nStudy 1:\n\n1. Age ≥ 18 years old.\n2. Acute ischemic stroke within 7 days of onset.\n3. Sign an informed consent form.\n\nStudy 2:\n\n1. Age ≥ 18 years old.\n2. Ischemic stroke during recovery period, within 30 days to 1 year of onset.\n3. Sign an informed consent form.\n\nStudy 3:\n\n1. Age ≥ 18 years old.\n2. Within 3 years, there are characteristic lesions of cerebral small vessel disease on head MRI or CT, and they meet at least one of the following criteria:\n\n   1. Paraventricular or deep white matter hyperintensities, Fazekas total score ≥ 2;\n   2. Paraventricular or deep white matter hyperintensities, Fazekas total score=1, and at least two vascular risk factors (hypertension, hyperlipidemia, diabetes, current smoking, obesity, history of coronary heart disease, history of stroke).\n   3. Paraventricular or deep white matter hyperintensities, Fazekas total score=1, with ≥ 1 lacune.\n   4. New recent subcortical small infarcts.\n3. Sign an informed consent form.\n\nExclusion Criteria:\n\nStudy 1:\n\n1. Cerebral hemorrhage and subarachnoid hemorrhage within 3 months of onset.\n2. There are untreated cerebral vascular malformations or untreated aneurysms (diameter\\>3mm).\n3. Confirmed neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Parkinson's syndrome, etc.\n4. A mental illness diagnosed according to the DSM-V diagnostic criteria.\n5. There are clear diagnoses of non-vascular white matter lesions, such as multiple sclerosis, adult white matter dysplasia, metabolic encephalopathy, etc.\n6. Unable to cooperate in completing follow-up visits due to geographical or other reasons.\n7. The patient also participated in other clinical trials.\n\nStudy 2:\n\n1. Cerebral hemorrhage and subarachnoid hemorrhage within 3 months of onset.\n2. There are untreated cerebral vascular malformations or untreated aneurysms (diameter\\>3mm).\n3. Confirmed neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Parkinson's syndrome, etc.\n4. A mental illness diagnosed according to the DSM-V diagnostic criteria.\n5. There are clear diagnoses of non-vascular white matter lesions, such as multiple sclerosis, adult white matter dysplasia, metabolic encephalopathy, etc.\n6. Unable to cooperate in completing follow-up visits due to geographical or other reasons.\n7. The patient also participated in other clinical trials.\n\nStudy 3:\n\n1. Cerebral hemorrhage and subarachnoid hemorrhage within 3 months of onset.\n2. There are untreated cerebral vascular malformations or untreated aneurysms (diameter\\>3mm).\n3. Confirmed neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Parkinson's syndrome, etc.\n4. A mental illness diagnosed according to the DSM-V diagnostic criteria.\n5. There are clear diagnoses of non-vascular white matter lesions, such as multiple sclerosis, adult white matter dysplasia, metabolic encephalopathy, etc.\n6. Unable to cooperate in completing follow-up visits due to geographical or other reasons.\n7. The patient also participated in other clinical trials.","ALL","18 Years",{"count":55,"type":56},20000,"ESTIMATED","OBSERVATIONAL","This study aims to construct a registry platform for microcirculatory disorders in a large sample of Chinese patients with cerebral small vessel disease and ischemic stroke; To explore the role of microcirculatory disorders in different types of cerebral small vessel disease and iachemic stroke, as well as their pathogenesis, severity, and prognosis; And to research on the drug treatment of microcirculatory disorders for cerebral small vessel disease and stroke in the real world.",[60,61],"Cerebral Small Vessel Diseases","Ischemic Stroke",[60,61,63,64,65],"Microcirculation Disorder","Multicenter Study","Registry Study","NOT_YET_RECRUITING","2023-10-18",{"date":69,"type":70},"2023-10-19","ACTUAL",{"date":72,"type":56},"2023-10-30",{"date":74,"type":56},"2026-12-31",{"name":5,"class":6},1]